发明名称 |
PHOSPHATIDYLINOSITOL-3-KINASE P110 DELTA-TARGETED DRUGS IN THE TREATMENT OF CNS DISORDERS |
摘要 |
Methods for treating CNS disorders such as schizophrenia, psychosis and cognitive disorders using specific inhibitors of phosphatidylinositol-3-kinase p110 delta (PIK3CD) expression and/or activity are described. Methods of determining risk of CNS disorders and methods of determining treatment response are also described. An integrative systems biology approach to identify a signaling mechanism and genetic network associated with schizophrenia and with schizophrenia-associated risk variation in ErbB4. A risk pathway associated with ErbB4 genetic variation involving increased expression of a PI3K-linked ErbB4 receptor CYT-1 and a specific PI3K enzyme, PIK3CD has been identified. |
申请公布号 |
CA2745280(A1) |
申请公布日期 |
2010.06.10 |
申请号 |
CA20092745280 |
申请日期 |
2009.12.04 |
申请人 |
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMEN T OF HEALTH AND HUMAN SERVICES |
发明人 |
LAW, AMANDA J.;WEINBERGER, DANIEL R. |
分类号 |
A61K31/517;A61K31/427;A61K31/506;A61K31/519;A61P25/00;A61P25/18;C12Q1/68;G01N33/68 |
主分类号 |
A61K31/517 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|